AMRI Appoints New Vice President of Chemical Development

AMRI Appoints New Vice President of Chemical Development


ALBANY, N.Y.--(BUSINESS WIRE)--Oct 12, 2010 - AMRI (NASDAQ: AMRI) announced today that David C. Lathbury, Ph.D. has joined the company as vice president of chemical development reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing.

Dr. Lathbury will assume leadership for AMRI's Chemical Development business including operations in Albany, Rensselaer and Syracuse, New York. He will also be responsible for the coordination of global projects spanning all AMRI chemical development operations, including the company's sites in Wales, United Kingdom and Hyderabad, India for purposes of further optimizing operations and technology transfer activities.

Dr. Lathbury brings over 23 years of industrial and leadership experience in process development and optimization, scale up and technical transfer of products in the pharmaceutical and agrochemical industry. Most recently, he served as director of process chemistry for AstraZeneca Process Research and Development (PR&D) where he was actively involved in setting global PR&D strategy for AstraZeneca's Discovery/PR&D interface and outsourcing functions. Prior to AstraZeneca, he spent seven years at Smithkline Beecham Pharmaceutical's Synthetic Chemistry division serving in roles of increasing responsibility focused on process development and technology transfer, culminating in the role of team leader. He has held additional leadership roles at both MTM Fine Chemicals as Chemistry Manager and at Shell Research's agrochemical discovery and process development as Senior Scientist.

Dr. Lathbury earned a Ph.D. in synthetic organic chemistry and B.Sc. in chemistry at Southampton University, located in the U.K. He also completed postdoctoral research at Cornell University and Bath University, located in the U.S. and the U.K. respectively.

"We are pleased to welcome Dr. Lathbury to the AMRI leadership team," said AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen. "His strong professional track record as both a scientific and functional leader will contribute significantly to our commitment to ensure that AMRI's standards for scientific excellence are consistent across our development operations worldwide."

"We are excited to recruit Dr. Lathbury at this critical time in the international expansion of our chemical development and manufacturing operations," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. "His depth of experience in setting and implementing strategy and tactical initiatives will make him a significant contributor to our efforts to further optimize the benefits of a fully integrated global process development and manufacturing operation."

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements regarding the company's clinical development plans for its proprietary compounds, the company's research programs and the license arrangement with BMS concerning the company's biogenic amines program. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to delay or denial of approvals from the FDA, potential changes in the cost, scope and duration of clinical trials as compared to the company's current expectations, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission on March 12, 2010 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.

 

 

Contact: Albany Molecular Research, Inc.
Media
Andrea Schulz, 518-512-2226
Corporate Communications
or
Investors
Peter Jerome, 518-512-2220
Director of Investor Relations

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.